Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

Archives of General Psychiatry

Volumn 59, Issue 4, 2002, Pages 337-345

  Newcomer, John W ^a   Haupt, Dan W ^a   Fucetola, Robert ^a   Melson, Angela K ^a   Schweiger, Julie A ^a   Cooper, Benjamin P ^a   Selke, Gregg ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZATROPINE MESILATE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DIPHENHYDRAMINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL DECANOATE; INSULIN; LITHIUM CARBONATE; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; RISPERIDONE; SERTRALINE; TEMAZEPAM; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0036215480     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.4.337     Document Type: Article

References (127)

1. Biochemical disturbances in mental disorders
2. Delayed action of insulin in schizophrenia
3. Carbohydrate metabolism in brain disease
4. Insulin sensitivity in schizophrenia
5. Glucose-insulin metabolism in chronic schizophrenia
6. A study of relationships of serum glucose, insulin, free fatty acids, and free and total tryptophan to mental illness
7. Glucose-induced increase in memory performance in patients with schizophrenia
8. Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia
9. Diabetes in chronic schizophrenia
10. A survey for unknown diabetics in a mental hospital, I: Men under age fifty
11. A survey for unknown diabetics in a mental hospital, II: Men from age fifty
12. Diabetes mellitus in schizophrenic patients
13. Family history of type 2 diabetes in schizophrenic patients
14. Phenothiazine derivatives and glucose metabolism
15. Phenothiazine-induced hyperglycemia: Relation to CNS and adrenal effects
16. Effect of chlorpromazine on blood glucose and plasma insulin in man
17. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
18. Drug-induced disorders of glucose tolerance
19. Hyperglycemia and glycosuria following chlorpromazine therapy
20. Hemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy
21. Chlorpromazine induced diabetes
22. Phenothiazines and diabetes in hospitalized women
23. A long-term follow-up of fluphenazine enanthate treatment
24. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
25. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis
26. Clozapine monotherapy and ketoacidosis
27. Clozapine and associated diabetes mellitus
28. Diabetic ketoacidosis from clozapine and lithium cotreatment
29. Diabetic ketoacidosis and clozapine
30. Severe hyperglycemia associated with high doses of clozapine
31. Ketoacidosis as a side-effect of clozapine: A case report
32. Diabetic ketoacidosis associated with clozapine treatment
33. Clozapine-induced diabetic ketoacidosis
34. Novel antipsychotics and new onset diabetes
35. Osmoregulation in clinical disorders of thirst appreciation
36. The effect of clozapine on glucose metabolism
37. Cutting the Gordian knot: Addition of metformin to insulin therapy in a patient with uncontrolled diabetes and schizophrenia
38. Schizophrenia and diabetes mellitus
39. Diabetic ketoacidosis associated with clozapine treatment
40. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
41. Diabetes mellitus associated with clozapine therapy
42. Clozapine can change glucose regulation in schizophrenia independent of body mass index (BMI)
43. Diabetic ketoacidosis with clozapine treatment
44. Hyperglycemia associated with olanzapine
45. Hyperglycemia and olanzapine
46. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
47. Diabetic ketoacidosis with olanzapine treatment
48. Olanzapine-induced glucose dysregulation
49. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
50. Diabetogenesis and ketoacidosis with atypical antipsychotics
51. New-onset diabetes mellitus associated with quetiapine
52. Nonextrapyramidal side effects of novel antipsychotics
53. Risperidone-associated diabetic ketoacidosis
54. Diabetic ketoacidosis associated with risperidone treatment?
55. Factors contributing to deaths of diabetics under fifty years of age
56. Characteristics of diabetic ketoacidosis in older versus younger adults
57. Olanzapine-induced ketoacidosis with diabetes mellitus
58. Acute-onset ketoacidosis during olanzapine treatment in a patient without pretreatment obesity or treatmentassociated weight gain
59. Hyperglycemia and ketoacidosis associated with olanzapine
60. Risperidone treatment for a patient suffering from schizophrenia and IDDM
61. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: A case series
62. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects
63. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity
64. Bodyweight change as an adverse effect of drug treatment: Mechanisms and management
65. The relationship of pharmacology to side effects
66. Antipsychotic-induced weight gain: A comprehensive research synthesis
67. Clozapine-induced weight gain: Prevalence and clinical relevance
68. Weight gain among schizophrenic patients treated with clozapine
69. Adverse effects of the atypical antipsychotics
70. Body weight and leptin plasma levels during treatment with antipsychotic drugs
71. Olanzapine-induced weight gain
72. Influence of oral glucose administration on working memory in schizophrenia
73. Differential effects of BMI on diabetes risk among black and white Americans
74. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994
75. Diagnostic interview for genetic studies: Rationale, unique features, and training
76. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
77. Relationship between fasting plasma glucose and glycosylated hemoglobin: Potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria
78. A brief psychiatric rating scale in psychopharmacology research
79. Four methods for glucose assay compared for various glucose concentrations and under different clinical conditions
80. Evaluation of automated glucose oxidase methods for serum glucose: Comparison to hexokinase of a colorimetric and an electrometric method
81. Determination of free and total insulin and C-peptide in insulin-treated diabetics
82. Immunoassays for glucagon
83. Plasma cortisol determination: Radioimmunoassay and competitive protein binding compared
84. The triumvirate: Beta-cell, muscle, liver: A collusion responsible for NIDDM: Lilly lecture 1987
85. The homeostasis model in the San Antonio Heart Study
86. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
87. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
88. Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia: Is mild hyperglycemia an underestimated evil?
89. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death
90. Long-term glycemic control relates to mortality in type II diabetes
91. Is glucose a continuous risk factor for cardiovascular mortality?
92. Antipsychotic-induced weight gain: A review of the literature
93. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate
94. Intra-abdominal fat: Is it a major factor in developing diabetes and coronary artery disease?
95. Effects of mood stabilizers on weight
96. Lithium carbonate-induced nephrogenic diabetes insipidus and glucose intolerance
97. Hyperglycemia associated with paroxetine
98. Diabetes mellitus in patients on lithium
99. Lithium in diabetes mellitus: A paradoxical response
100. Effects of nortriptyline on depression and glycemic control in diabetes: Results of a double-blind, placebo-controlled trial
101. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain
102. Valproate causes metabolic disturbance in normal man
103. Fluoxetine therapy in obese diabetic and glucose intolerant patients
104. Evaluation of three potential screening tests for diabetes mellitus in a biethnic population
105. The hormone resistin links obesity to diabetes
106. 2 receptor agonists DOI and α-methyl-5-HT on plasma glucose and insulin levels in the rat
107. 1A receptor agonist, ipsapirone, does not affect 8-OH-DPAT-and stress-induced increases in plasma adrenaline levels in the rat
108. 2A receptor in peripherally administered serotonin-induced hyperglycemia in rats
109. Hyperglycemic properties of serotonin receptor antagonists
110. The effects of the serotonin 1A receptor agonist buspirone on tolbutamide-induced hypoglycemia in rats
111. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat
112. A kinetic study of chlorpromazine on the hyperglycemic response in rats II: Effect of chlorpromazine on plasma glucose
113. Effects of chlorpromazine and epinephrine on blood-sugar of rabbits
114. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells
115. Hyperglycemic crises in urban blacks
116. Type 2 diabetes mellitus: The grand overview
117. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: The Rancho Bernardo Study
118. Coronary-heart-disease risk and impaired glucose tolerance: The Whitehall study
119. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study
120. Body weight gain induced by antipsychotic drugs: Mechanisms and management
121. Olanzapine-induced elevation of plasma triglyceride levels
122. Elevated serum triglycerides with clozapine resolved with risperidone in four patients
123. Clozapine-associated elevation in serum triglycerides
124. Serum triglyceride levels in patients treated with clozapine
125. Patients with schizophrenia who smoke: Private disaster, public resource